Results 221 to 230 of about 353,583 (326)

A Novel Series of Synthetic Heparin‐Mimetics–Itaconic Acid‐Containing Copolymers for Targeting Tumor Cell Coagulability and Metastasis

Macromolecular Bioscience, Volume 25, Issue 7, July 2025.
Heparin is postulated to possess antitumor properties‐ beyond its anticoagulative activities in oncology, but disclosure of targeted activities is complicated by heparins structural variabilities as natural glycosaminoglycans. Here, synthetic noncarbohydrate polymers are presented with tuneable structures as heparin mimetics in in‐vitro‐approaches for ...
Katrin Nekipelov, Abdullah Al Nahain, Sven Otto, Yongbin Xu, Jin‐Ping Li, Natasha Letunica, Simon Collett, Chantal Attard, Paul Monagle, George Vamvounis, John Tsanaktsidis, Vito Ferro, Gerd Bendas   +12 more
wiley   +1 more source

Rare Prekallikrein Deficiency Identified During Workup of Isolated Prolonged Activated Partial Thromboplastin Time. [PDF]

Ochsner J
Woo JS, Tseng J, Kang IM, Zhuang L, Jackson R, Danilova OV, Borogovac A.   +6 more
europepmc   +1 more source

Evaluation of a Best Practice Advisory on Ordering Prothrombin Time, International Normalized Ratio, and Partial Thromboplastin Time Tests.

JAMA Intern Med, 2022
Breeden M, Bernstein SJ, Hayward RA, Fendrick AM.   +3 more
europepmc   +1 more source

Laboratory Monitoring of Heparin Therapy: Partial Thromboplastin Time or Anti-Xa Assay?

, 2008
Christopher M. Lehman, Elizabeth L. Frank   +1 more
openalex   +1 more source

The Biomaterial and Blood Clot Complex: A Crucial Early Environment for Osteo‐Coagulo‐Immunomodulation and the Advancement of Bone Biomaterials

Small Structures, Volume 6, Issue 7, July 2025.
Various properties of bone biomaterials can modulate components of the blood clot (including the fibrin network, red blood cells, platelets, and the complement system) in vivo implantation, leading to the formation of a biomaterial–blood clot complex (BBCC) significantly impacting subsequent osteoimmunomodulation.
Zongpu Han, Jieyun Xu, Xinyu Guo, Lingyu Liang, Linjun Zhang, Yu Su, Wendong Gao, Qingming Tang, Lili Chen, Zhuofan Chen, Yin Xiao, Zetao Chen   +11 more
wiley   +1 more source

Elevated Activated Partial Thromboplastin Time as a Predictor of 28-Day Mortality in Sepsis-Associated Acute Kidney Injury: A Retrospective Cohort Analysis. [PDF]

Int J Gen Med
Lin C, Wang J, Cai K, Luo Y, Wu W, Lin S, Lin Z, Feng S.   +7 more
europepmc   +1 more source

Discordant Partial Thromboplastin Time (PTT) vs Anti-Xa Heparin Activity [PDF]

, 2018
Jenna Khan, Wayne L. Chandler
openalex   +1 more source

Profound Thrombocytopenia and Dyspnea 11 Days After Cardiac Surgery

American Journal of Hematology, Volume 100, Issue 7, Page 1234-1239, July 2025.
Sebastian Vuong, Menaka Pai, Sarah Patterson, Theodore E. Warkentin   +3 more
wiley   +1 more source

Successful Management of Presumed Reactivation of Neospora caninum Following Immunosuppression for Immune Thrombocytopenia in an Adult Doberman

Veterinary Medicine and Science, Volume 11, Issue 4, July 2025.
Positive serology titres for Neospora caninum in the absence of appropriate clinical signs is not diagnostic for protozoal disease. Acute deterioration while immunosuppressed should raise concerns over reactivation of encysted protozoa, particularly in dogs with a history of raw feeding. Successful management of N. caninum appears possible but requires
Perrine Henry, Paul Rees, Tyler Morrison, Glynn Woods   +3 more
wiley   +1 more source

Impact of as Needed Heparin Boluses on Supratherapeutic Activated Partial Thromboplastin Time in Patients Managed With Extracorporeal Membrane Oxygenation. [PDF]

Crit Pathw Cardiol
Corcoran DM, Kovacevic MP, Dell'Orfano H, Sylvester KW, Connors JM.   +4 more
europepmc   +1 more source